度戈妥珠单抗
化合物
度戈妥珠单抗（INN：Duligotuzumab）是一种双特异性人源化IgG1单克隆抗体，设计用于治疗癌症。它充当免疫调节剂并与EGFR和HER3结合。[1][2]它由罗氏公司开发。针对头颈癌和结直肠癌的临床开发已停止，但与考比替尼联合使用的I期试验正在评估实体瘤治疗的安全性。[3]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | HER3 |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1314238-96-4 |
| ChemSpider |
|
| UNII | |
| KEGG | |
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-22]. （原始内容存档 (PDF)于2016-03-04）.
- ^ Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Alfonso, Pilar Garcia; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Jeffery, Mark; Bartolomeo, Maria Di. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2018-05-15, 24 (10) [2024-01-22]. ISSN 1557-3265. PMID 29506988. doi:10.1158/1078-0432.CCR-17-0646. （原始内容存档于2024-03-14）.
- ^ Duligotuzumab. AdisInsight. [2024-01-22]. （原始内容存档于2021-11-19）.